Lone voice2 Jun 2020 18:22
I may be a lone voice here, whilst any dilution is never received well by holders, personally I think it is no bad thing them continuing alone. The further they get down the road of developing the drugs, the higher the less risk there is for a big pharma and an increased value when we come to sell. I believe they have a plan, the Β£200k grant being awarded to the scientist who was working on our drug was announced last week, I think there is more news in the offing. I am glad a decision was made, doing nothing was the problem, now we have a direction.